
Editas Medicine Reports Q4 2024 Earnings and Provides Business Updates: A Look at the Company’s Fourth Quarter and Full-Year Financial Results
Exciting Advancements in Gene Editing: A Look into the Future of In Vivo Therapies In the ever-evolving world of gene editing, a groundbreaking biotech company is on the brink of making history. With a strong focus on in vivo editing, they are expected to declare two development candidates via gene upregulation by mid-2025. Let’s delve…